Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT
Suhrad G Banugaria, Sean N Prater, Trusha T Patel, Stephanie M Dearmey, Christie Milleson, Kathryn B Sheets, Deeksha S Bali, Catherine W Rehder, Julian A J Raiman, Raymond A Wang, Francois Labarthe, Joel Charrow, Paul Harmatz, Pranesh Chakraborty, Amy S Rosenberg, Priya S Kishnani, Suhrad G Banugaria, Sean N Prater, Trusha T Patel, Stephanie M Dearmey, Christie Milleson, Kathryn B Sheets, Deeksha S Bali, Catherine W Rehder, Julian A J Raiman, Raymond A Wang, Francois Labarthe, Joel Charrow, Paul Harmatz, Pranesh Chakraborty, Amy S Rosenberg, Priya S Kishnani
Abstract
Objective: Although enzyme replacement therapy (ERT) is a highly effective therapy, CRIM-negative (CN) infantile Pompe disease (IPD) patients typically mount a strong immune response which abrogates the efficacy of ERT, resulting in clinical decline and death. This study was designed to demonstrate that immune tolerance induction (ITI) prevents or diminishes the development of antibody titers, resulting in a better clinical outcome compared to CN IPD patients treated with ERT monotherapy.
Methods: We evaluated the safety, efficacy and feasibility of a clinical algorithm designed to accurately identify CN IPD patients and minimize delays between CRIM status determination and initiation of an ITI regimen (combination of rituximab, methotrexate and IVIG) concurrent with ERT. Clinical and laboratory data including measures of efficacy analysis for response to ERT were analyzed and compared to CN IPD patients treated with ERT monotherapy.
Results: Seven CN IPD patients were identified and started on the ITI regimen concurrent with ERT. Median time from diagnosis of CN status to commencement of ERT and ITI was 0.5 months (range: 0.1-1.6 months). At baseline, all patients had significant cardiomyopathy and all but one required respiratory support. The ITI regimen was safely tolerated in all seven cases. Four patients never seroconverted and remained antibody-free. One patient died from respiratory failure. Two patients required another course of the ITI regimen. In addition to their clinical improvement, the antibody titers observed in these patients were much lower than those seen in ERT monotherapy treated CN patients.
Conclusions: The ITI regimen appears safe and efficacious and holds promise in altering the natural history of CN IPD by increasing ERT efficacy. An algorithm such as this substantiates the benefits of accelerated diagnosis and management of CN IPD patients, thus, further supporting the importance of early identification and treatment initiation with newborn screening for IPD.
Conflict of interest statement
Competing Interests: SGB, SNP, TTP, CM, KBS, CWR, FL, PC, and ASR have no financial or proprietary interest in the materials presented herein. SMD has received honoraria from Genzyme. DSB reports receiving research and grant support from Genzyme. JAR has received travel support, speaker fees and his department has received unrestricted educational grants from Genzyme. RYW has a material interest in Biomarin Pharmaceuticals, is a member of the Genzyme/Sanofi Aventis North American Board of Advisors for MPS I, and has received research support from Shire plc. He has received travel and lodging support for attendance to scientific meetings from Genzyme/Sanofi Aventis as well as from Shire plc, and is the local study site principal investigator for the Genzyme/Sanofi Aventis Lumizyme phase III extension trial. JC is a member of the Fabry and Gaucher Disease Registry Advisory Board for Genzyme Corporation. He has received honoraria from Genzyme Corporation. PH has received educational grants, travel support to scientific meetings and speaker's honorarium from Genzyme Corporation. PSK reports receiving research and grant support from Genzyme. PSK also receives honoraria and consulting fees from Genzyme and is a member of the Pompe disease and the Gaucher Disease Registry Advisory Boards. Duke University and the inventors of the method of treatment and precursors of the cell lines used to generate the enzyme (rhGAA) used commercially have received royalties pursuant to the University's policy on inventions, patents, and technology transfer. This potential conflict for Duke University has been resolved through monetization. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Figures
References
- Hers HG (1963) alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease). Biochem J 86: 11–16.
- Hirschhorn R, Reuser AJJ, editors (2009) Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency New York: McGraw-Hill.
- Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, et al. (2009) Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11: 210–219.
- Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, et al. (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68: 99–109.
- Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, et al. (2006) Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149: 89–97.
- Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, et al. (2009) Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 66: 329–335.
- Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, et al. (2009) Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 124: e1116–1125.
- Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, et al. (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99: 26–33.
- Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS, et al. (2011) The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 13: 729–736.
- Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, et al. (2012) Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 14: 135–142.
- Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS (2009) Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med 360: 194–195.
- Banugaria SG, Patel TT, Mackey J, Das S, Amalfitano A, et al. (2012) Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab 105: 677–680.
- Hunley TE, Corzo D, Dudek M, Kishnani P, Amalfitano A, et al. (2004) Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics 114: e532–535.
- Banugaria SG, Patel TT, Kishnani PS (2012) Immune modulation in Pompe disease treated with enzyme replacement therapy. Expert Rev Clin Immunol 8: 497–499.
- Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, et al. (2012) Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet 160: 40–49.
- Kaplan EL, Meier P (1958) Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association 53: 457–481.
- Rohrbach M, Klein A, Kohli-Wiesner A, Veraguth D, Scheer I, et al. (2010) CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 33: 751–757.
- Khallaf HA, Propst J, Geffrard S, Botha E, Pervaiz MA (2013) CRIM-Negative Pompe Disease Patients with Satisfactory Clinical Outcomes on Enzyme Replacement Therapy. In: Zschocke J, Gibson KM, Brown G, Morava E, Peters V, editors. JIMD Reports - Case and Research Reports, 2012/6: Springer Berlin Heidelberg. 133–137.
- Abbott MA, Prater SN, Banugaria SG, Richards SM, Young SP, et al. (2011) Atypical immunologic response in a patient with CRIM-negative Pompe disease. Mol Genet Metab 104: 583–586.
- Banugaria SG, Prater SN, McGann JK, Feldman JD, Tannenbaum JA, et al... (2012) Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med.
- Hall PD (1993) Immunomodulation with intravenous immunoglobulin. Pharmacotherapy 13: 564–573.
- Rigter T, Weinreich SS, van El CG, de Vries JM, van Gelder CM, et al. (2012) Severely impaired health status at diagnosis of Pompe disease: A cross-sectional analysis to explore the potential utility of neonatal screening. Mol Genet Metab 107: 448–455.
- Moyer VA, Calonge N, Teutsch SM, Botkin JR (2008) Expanding newborn screening: process, policy, and priorities. Hastings Cent Rep 38: 32–39.
- Anthony RM, Kobayashi T, Wermeling F, Ravetch JV (2011) Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475: 110–113.
- Rezvani AR, Maloney DG (2011) Rituximab resistance. Best Pract Res Clin Haematol 24: 203–216.
- Prater SN, Banugaria SG, DeArmey SM, Botha EG, Stege EM, et al. (2012) The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med 14: 800–810.
Source: PubMed